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Abstract
Cancer is one of the world’s most lethal diseases. Although our understanding of this disease
is expanding continuously, treatments for many types of cancers are still insufficient. The
main reason for the high mortality of cancer patients is resistant to therapy. Since resistance
to therapy is a complex and dynamical process, an interdisciplinary approach is necessary to
understand it.
The emergence of a new field called integrative mathematical oncology can tackle many
urgent clinical problems in the treatment of cancer that are impossible to address using, for
example, an in vitro or in vivo approach. The primary goal of this new field is to translate the
biological complexity of a tumor into a precise language, such as mathematical formulas,
and to perform model simulations. Therefore, integrative mathematical oncology allows for
biological experiments to be performed inexpensively and rapidly.
This thesis applies the integrative mathematical oncology (IMO) approach to investigate
resistance to treatment in solid tumors at the molecular and cellular levels. A mathematical
model of the most commonly dysregulated pathway in cancer (the p53 signaling pathway)
underwent a bifurcation analysis to investigate the possibility of restoring its proper dynamics
in two types of cancer: osteosarcoma and breast cancer. Next, a stochastic model of resistance
to platinum compounds was developed to improve our understanding of chemo-resistance to
this group of drugs in advanced high-grade serous ovarian cancer (HGSOC). Finally, virtual
clinical trial simulations (VCTS) were performed to identify a novel drug combination in
ovarian cancer.
The application of integrative mathematical oncology deepened our understanding of radio-
and chemo-resistance in solid tumors. Firstly, the results from the bifurcation analysis of the
p53 signaling pathway suggested silencing Mdm2 using siRNA to overcome radio-resistance
in breast cancer and osteosarcoma. Next, the stochastic model of platinum resistance was
utilized to answer two urgent clinical questions about ovarian cancer: i) how many platinum
resistance mechanisms are active at diagnosis, and ii) how many drug-resistance mechanisms
must be targeted to improve patient outcomes. Finally, the clinical trial simulations suggested
a novel drug combination to overcome platinum resistance in advanced high-grade serous
ovarian cancer.
Streszczenie
Rak jest jedna˛ z najbardziej s´miertelnych chorób na s´wiecie. Pomimo tego, z˙e wiedza na
temat tej choroby jest cia˛gle rozwijana, terapia w przypadku wielu typów nowotworów
jest nieefektywna. Głównym powodem wysokiej s´miertelnos´ci pacjentów chorych na raka
jest opornos´c´ na terapie˛. Jakoz˙e opornos´c´ na terapie˛ jest skomplikowanym i dynamicznym
procesem, interdyscyplinarne podejs´cie jest niezbe˛dne do jego zrozumienia.
Pojawienie sie˛ nowej dziedziny zwanej zintegrowana˛ matematyka˛ onkologiczna˛ jest w stanie
rozwia˛zac´ wiele waz˙nych problemów klinicznych, które sa˛ niemoz˙liwe do rozwia˛zania
przy uz˙yciu in vitro lub in vivo. Głównym celem tej nowej dziedziny jest przetlumaczenie
biologicznej złoz˙onos´ci nowotworów na precyzyjny je˛zyk, taki jak formuły matematyczne, i
wykonanie symulacji modelów. Dlatego zintegrowana onkologia matematyczna umoz˙liwia
wykonanie eksperymentów biologicznych szybko oraz bez duz˙ych nakładów finansowych.
W tej pracy, podejs´cie matematyki onkologicznej zostało wykorzystane do zrozumienia
opornos´ci zbitych nowotworów na leczenie w dwóch skalach: molekularnej i komórko-
wej. Najpierw, model matematyczny najbardziej rozregulowanej s´ciez˙ki sygnałowej w raku
(s´ciez˙ce sygnałowej p53) został poddany analizie bifurkacji celem zbadania moz˙liwos´ci
przywrócenia prawidłowej dynamiki tej s´ciez˙ki sygnałowej w dwóch nowotworach: kost-
niakomiessakach i nowotworach piersi. Naste˛pnie, stochastyczny model lekoopornos´ci na
platyne˛ został wykonany celem zrozumienia mechanizmów lekoopornosci na platyne˛ w
zaawansowanym surowiczym raku jajnika. Na koniec, virtualne symulacje prób klinicznych
zostały wykonane celem zidentyfikowania nowych kombinacji leków w raku jajnika
Zasosowanie zintegriwanej matematyki onkologicznej pogłe˛biło nasza˛ wiedze˛ o opornosci
na radio- i chemo-terapie˛ w nowotworach zbitych. Najpierw, wyniki z analizy bifurkacyjnej
s´ciez˙ki sygnałowej p53 proponuje wyciszenie Mdm2 przy uz˙yciu siRNA celem pokonania
radioopornos´ci w raku piersi i kostniakomie˛saku. Naste˛pnie, stochastyczny model opornosci
na platyne˛ został wykoz˙ystany celem odpowiedzi na dwa pilne pytania kliniczne: i) ile
mechanizmów opornos´ci na platyne˛ jest aktywnych podczas diagnozy i ii) ile mechanizmów
lekoopornosci na platyne˛ nalezy celowac´ celem poprawy przez˙ywalnos´ci. Na koniec, symu-
lacje prób klinicznych sugeruja˛ nowa˛ kombinacje˛ leków celem pokonania lekoopornos´ci na
platyne˛ w surowiczym raku jajnika.
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1 INTRODUCTION
1 Introduction
Cancer’s key trait is the disruption of the balance between cell proliferation and
cell death, resulting in uncontrolled tumor growth, invasion, and metastasis. Cancer
is a complex disease in which (epi)genetic alternations occur at the subcellular
level and lead to functional changes at the cellular and tissue levels. Therefore,
cancer is believed to be a multi-scale process where understanding each scale
and connection between them requires a holistic approach, such as data-driven
mathematical modeling [1].
Applying mathematics to oncology is relatively new. The field aims to describe
cancer on multiple levels, such as the molecular and cellular levels, using mathemat-
ical formulas [2]. A constructed model can be then analyzed using mathematical
methods, or simulated numerically to improve our understanding of cancer and
suggest novel treatment modalities. As more and more omics and clinical data are
collected, mathematical models of cancer can be calibrated and validated leading to
more accurate results from model simulations. Moreover, recent advancements in
mathematics and availability of high computing power allow for the simulation of
complex individual-based and multiscale models [3, 4]. As a result, a new subfield
of oncology called integrative mathematical oncology (IMO) has emerged [5].
IMO is at the intersection of mathematics and oncology where the goal is to
understand cancer from a mechanistic viewpoint [6]. By translating the biological
complexity of such a complex disease into mathematical language, IMO describes
cancer-related phenomena through an emerging outcome that is predicted by model
simulations. IMO can be divided into two subfields: computational and physical
one [7]. The first one uses high-throughput data, such as genomics or proteomics,
to build models that can quantitatively predict the patient’s outcome. For instance,
the phylogenetic model of tumor evolution can be constructed to understand the
evolution of tumor progression [8]. Physical oncology, which is the focus of this
thesis, views cancer as a complex biological system and aims to create mechanistic
models of tumorigenesis and cancer progression. This subfield contributes for
example to the understanding of treatment resistance in cancer, among other things
[9].
IMO approach has been applied to answer a wide range of questions in oncology.
For example, it was used to investigate the effectiveness of cancer screening [10],
suggest novel drug combinations [11], understand complex interactions in the tumor
microenvironment [12], suggest more optimal drug scheduling [13], and estimate
the probability of metastasis [14]. However, IMO is still an emerging field and only
a few mathematical models have been translated into clinical practice successfully
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[15].
This thesis aims to suggest novel methods to overcome resistance to therapy in
solid tumors using integrative mathematical oncology approach. The thesis focuses
on radio- and chemo-sensitivity on the molecular and cellular levels. First, a model
of the p53 signaling pathway for two types of cancer (osteosarcoma and breast
cancer) is developed to investigate resistance to ionizing radiation (IR). The results
of the model analysis suggest silencing Mdm2 as a means to overcome radio-
resistance. Next, a model of resistance to platinum compounds is developed and
applied to find a method to revert resistance to platinum-based chemotherapy in
advanced HGSOC. Finally, virtual clinical trials simulations are employed to test
the effectiveness of combining platinum with drugs that target specific platinum-
resistance mechanisms.
2
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2 Cancer
In order to survive, all living organisms require constant maintenance of stability
called homeostasis. In human body, blood pressure, blood sugar, oxygen, pH,
and temperature, among other things, are constantly being adjusted to maintain a
constant level. It means the human body is in a constant dynamic equilibrium [16].
Disruption of this mechanism leads to various diseases, such as cancer.
In order to maintain homeostasis, the number of cells in the adult human body
is kept constant, and cell division usually occurs to replace dead cells [17]. This
process is controlled in the cell through the regulation of cellular growth and
death signals. An imbalance between the signals to divide and die can lead to
carcinogenesis. Therefore, on the most basic level, cancer can be defined as a
disease of uncontrolled cell growth and cell division [18].
Cancer is not a single disease, but rather, a group of disorders that can be divided
by type of origin tissue (histology) or location in the body (primary site) [19].
The National Cancer Institute defines over 200 types of cancer [20], and the most
common type (80% of all cancer cases) is epithelial one [21].
Tumors are usually divided into two categories: solid and hematological malignancy.
Solid tumors, which are the focus of this thesis, are defined as abnormal clumps
of cells that typically do not contain liquids or cysts [22]. Hematological cancers,
instead, usually do not form a tumor. Instead, they originate in the blood, bone
marrow, or lymphatic system and include leukemia, lymphoma, and myeloma.
2.1 Ovarian cancer
In 2018, 295,414 of new ovarian cancer cases were diagnosed, and 184,799 women
died [23]. Ovarian cancer is the eight most common cancer in women and ranks
as the fifth cause of deaths related to cancer among women. Ovarian cancer has a
high mortality rate because it is usually diagnosed at advanced stages due to the
absence of accurate screening methods and also unspecific symptoms in the early
stage [24].
Ovarian cancer is a disease that originates from the epithelial, germ, or stromal cell
[25]. Epithelial ovarian cancer is the most common subtype of ovarian cancer and
constitutes 95% of all cases [26]. Two-thirds of all epithelial tumors are serous and
can be divided into two groups: low-grade (10%) and high-grade (90%). Therefore,
HGSOC, which is the focus of this thesis, is the most common subtype of ovarian
cancer, accounting for approximately 70% of all ovarian cancer cases [27].
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High grade serous ovarian cancer is not a single disease, but rather a family of
non-uterine ovarian cancers originating from an epithelial cell [28, 29]. It is the
most aggressive histological subtype of ovarian cancer. Although the five–years
survival of early-stage patients is higher than 80%, the advanced HGSOC has the
five–years survival rate below 30% [30]. HGSOC is characterized by a mutation
in the p53 gene, high genomic instability, the high number of DNA copy number
variations, and few somatic mutations [31].
2.1.1 Standard of care in HGSOC
The first–line treatment for ovarian cancer depends on tumor stage, dissemination to
other organs, and patient’s physical condition. This section describes the standard
treatment protocol for newly diagnosed advanced ovarian cancer following the
current clinical practice guidelines [32, 33]. Figure 1 presents a schematic of the
standard of care (SOC).
When ovarian cancer is suspected, two types of clinical assessment are performed:
blood tests to measure cancer biomarkers (such as CA-125 and HE4), and CT scans
to determine if a pelvic mass is malignant. The National Comprehensive Cancer
Network (NCCN) guidelines suggest using these measurements together with an
algorithm called the Risk of Ovarian Malignancy Algorithm (ROMA) [34].
After diagnosing advanced ovarian cancer, a laparoscopy is performed to evaluate
whether optimal cytoreduction is possible since the residual tumor burden is a
key clinical parameter that correlates with patients’ outcomes [35]. Optimal
cytoreduction means that the residual tumor nodules have a maximum diameter
of 1 cm. The patients are assigned to one of two treatment groups, as indicated in
Figure 1. The first group is called the primary debulking surgery group (PDS), and
the second group is called the neoadjuvant treatment group (NACT).
When optimal debulking is possible at the time of diagnosis, the patient is assigned
to the PDS group where primary debulking surgery is performed to remove the
ovaries, fallopian tubes, and uterus. Next, the patient undergoes at least six cycles
of platinum-taxane chemotherapy administered intravenously with a three-weeks
interval.
If optimal debulking is not possible, an alternative solution is administering neoadju-
vant chemotherapy (NACT). Usually, three cycles of platinum-taxane chemotherapy
or platinum alone are administered. After NACT, clinical evaluation is performed to
check if the tumor is operable by measuring the CA-125 biomarker and performing
computed tomography (CT) scans. If the tumor is operable, interval debulking
surgery (IDS) is performed following another three cycles of adjuvant chemotherapy
4
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(ADJ). If the patient is inoperable after NACT, they are referred to alternative or
palliative treatment.
Figure 1: Schematic of primary treatment in advanced HGSOC. NACT = neoadjuvant
chemotherapy; PDS = primary debulking surgery; IDS = interval debulking surgery;
ADJ = adjuvant chemotherapy.
2.2 Models of carcinogenesis
One of the hallmarks of cancer is the ability of cancer cells to sustain proliferative
signals [36]. Healthy cells control the release of growth-promoting signals carefully.
However, cancer cells continually emit proliferative signals that permit their survival
and abnormal proliferation [37]. Many theories have attempted to explain how
sustaining proliferating signaling drive carcinogenesis [38]. Figure 2 presents the
two most well-known theories, which are called hierarchical and the stochastic
model.
The clonal evolution model (or stochastic model) assumes that cancer is initiated
from a healthy cell through the accumulation of (epi)genetic changes. These
changes accumulate in cancer cells, leading to the appearance of various subclones
with a different spectrum of (epi)genetic aberrations. Some changes confer a
selective advantage and allow the clone to out-compete other ones. This model
of carcinogenesis assumes that all subclones have the potential for self-renewal.
Therefore, all clones need to be targeted by a chemotherapeutic agent in order to
eradicate the entire tumor [39].
Hierarchical model, the growth of the tumor is only dependent on a small fraction of
cancer cells called cancer stem cells (CSCs). Cancer is initiated from a single CSC
that undergoes differentiation and has the potential for self-renewal. Therefore, the
tumor is assumed to be composed of a small population of CSCs that are responsible
for tumor growth and a large fraction of differentiated cancer cells that have lost
the potential for self-renewal. In this model, treatment only targets CSCs because
they are the only cells that contribute significantly to tumor perpetuation [40].
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Figure 2: Two models of carcinogenesis: cancer stem cell (hierarchical) and clonal
evolution (stochastic). The cancer stem cell model proposes that cancer is initiated
by cancer stem cells (CSCs) that are pluripotent and self-renewing. CSCs divide
unfaithfully, leading to the appearance of differentiated cells (blue). In the clonal
evolution model, cancer is initiated through a cancer cell that can acquire new mutations,
leading to the appearance of a new subclone. Adapted from [40].
2.3 Tumor evolution
Cancer is subjected to the same evolutionary forces, such as selection and genetic
drift, like other evolutionary systems [39, 41]. Evolutionary theories about neoplasm
are crucial for understanding tumor progression and the resistance to treatment,
among other processes [42]. The current belief is that understanding the ecological
and evolutionary properties of a tumor could help clinicians suggest better treatment
strategies and predict responses to therapies [43]. Therefore, understanding tumor
evolution and intra-tumor heterogeneity (ITH) are essential for improving patient
survival.
The theory of cancer evolution suggests that carcinogenesis is a multi-stage process
with three major steps: initiation, promotion, and progression (see Figure 3). In the
first phase, (epi)genetic alternations are acquired by a healthy cell, leading to the
appearance of a tumor-initiating cell. The process is called tumor initiation. Next,
tumor promotion leads to selective clonal expansion of tumor-initiating cells and
the production of a large population of pre-neoplastic cells that become at risk of
6
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conversion. The last phase of multistage carcinogenesis is tumor progression. Here,
a tumor cell arises and divides into malignant cells which initially form a benign
tumor and then spread to distant organs through a process called metastasis.
As a result of evolutionary forces, a tumor composes of many types of cancer cells
(subclones) that have accumulated different (epi)genetic aberrations, leading to
ITH. It is why, even though, the administration of first-line therapy to the tumor,
often leads to a successful reduction of its mass, the same treatment also applies
Darwinian selection for drug-resistant clones. Therefore, it is suggested that the
aim of cancer treatment should not be to remove as many cancer as possible in
a short timeframe, but rather treatment should focus on targeting drug-resistant
subclones [44].
Figure 3: Multistage tumorigenesis.
2.4 Cancer treatment
Cancer can be treated using various strategies, including surgery, chemotherapy,
radiotherapy, and targeted therapy. The type of treatment depends on the tumor’s
location, stage, and the patient’s overall condition. Treatments can be adminis-
tered in combination. For example, for advanced HGSOC patients, surgery and
chemotherapy are used as a first-line treatment [45].
The current paradigm considers cancer a local disease that sometimes later spreads
to distant organs [46]. Based on this paradigm, it is suggested that the primary
treatment of solid tumors should include surgery. Therefore, removal of tumor cells
could cure the patient, if cancer has not spread to other organs. Indeed, surgery is a
key treatment intervention for breast and ovarian cancer [47, 48].
Chemotherapy involves the administration of chemicals to inhibit the growth of
malignant cells. The rationale behind chemotherapy is that fast-dividing cancer cells
are more sensitive to DNA damage and, therefore, most prone to chemotherapy-
induced death [49]. The goal of chemotherapy depends on the stage of the
tumor and the patient’s general condition. For example, induction chemotherapy
is administered as a first-line treatment to cure the patient, while consolidation
chemotherapy is administered after remission to prolong the patient’s survival [50].
Targeted therapy is one of the most commonly applied strategies in cancer treatment
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nowadays, and targets the molecules needed for carcinogenesis and tumor growth
rather than focusing on fast-dividing cells [51]. There are two major types of
targeted-therapy drugs: one blocks the actions of specific proteins involved in
spreading cancer (e.g., PARPi in ovarian cancer) [52] and the other targets the
immune system to kill cancer cells (e.g., PD-L1 inhibitors in ovarian cancer) and is
called immunotherapy [53]. The goal of targeted therapy is to specifically target
cancer cells without affecting healthy cells.
Radiotherapy is a type of treatment that uses a high dose of radiation (e.g., X-
rays or gamma rays) to kill cancer cells [54]. There are two ways to administer
radiotherapy: external beam radiation therapy and internal radiation therapy. High-
energy ionizing radiation (IR) damages DNA, thus blocking the ability of cancer
cells to divide. Radiotherapy kills both healthy and cancer cells, but cancer cells
are less proficient at repairing DNA damage caused by IR.
8
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3 Treatment resistance in cancer
Administering chemotherapeutic drugs, such as cisplatin, shows excellent initial
response [55, 56]. However, after a short time, tumor recurrence is often observed
with the tumor resistant to chemotherapy. As a result, multi-drug resistance (MDR)
emerges. Therapy resistance can be divided into two major groups: intrinsic (pre-
existing) and acquired [57]. Intrinsic therapy resistance means that mediating
factors, such as mechanical or biochemical factors, existed in the tumor before the
treatment was administered. Alternatively, acquired therapy resistance develops
during treatment as a result of (epi)genetic aberrations in tumors that were initially
sensitive to therapy [58]
Figure 4 presents the two main mechanisms of therapy resistance, which are
alternations in the drug metabolism and modifications to the drug target [59].
The next section describes both mechanisms of therapy resistance.
Figure 4: Mechanism of drug resistance to chemotherapy in cancer. Adapted from [59].
3.1 Types of treatment resistance in cancer
The most widely studied mechanisms of drug resistance are those caused by
alternations in drug metabolism. These alternations can be divided into three
categories: reduced drug uptake, drug detoxification, and increased drug efflux.
Transport of chemotherapeutic drugs (driven mostly by cell receptors) depends on
its chemical properties. Resistance can be caused by mutations that modify the
activity of cell receptors or transporters, such alternations in the copper transporter
receptor 1 (CTR1) in ovarian cancer [60]. The second mechanism of drug resistance
is caused by aberrations in metabolism due to increased drug efflux. For instance,
increased expression of the ATP-binding cassette (ABC) membrane transporters
correlates with resistance to doxorubicin [61]. Finally, drug deactivation can happen
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before it binds to its target. For example, glutathione (GSH) is shown to inactivate
platinum drugs [61].
Modification of a drug target is another type of drug resistance in cancer. The
effectiveness of a specific drug depends on its ability to bind to its target, such
as DNA. Mutations in the drug target could lead to the production of a protein
with a modified binding site. Therefore, binding becomes impossible, even if the
drug reaches its target. For instance, PARP inhibitors (PARPi) are administered
to treat ovarian cancer patients with a mutation in BRCA1/2. However, a sponta-
neous mutation could reverse the original mutation in this gene, leading to drug
resistance [62].
In addition to the cellular mechanisms of treatment resistance, non-cellular ones
are also observed, especially in solid tumors [63]. These non-cellular mechanisms
involve interactions between cancer cells and a different component in the tumor
microenvironment. For instance, response to chemotherapy is influenced by the
vasculature since chemotherapeutic drugs gain access to tumor cells via the blood
vessels. It is known that blood-flow in a tumor is variable and disorganized, which
results in a hypoxic region where the drug cannot enter [64].
3.2 Methods to overcome treatment resistance in cancer
To overcome drug resistance in cancer patients, drug scheduling and chemothera-
peutic agents are usually changed. However, these approaches cannot always be
applied because patients gain drug resistance to multiple agents over time, leading
to MDR. This section discusses the most common strategies for overcoming drug
resistance in cancer patients.
The first method to re-sensitize cancer cells to treatment is to find analogs to one of
the most widely administered chemotherapeutic agents. For instance, doxorubicin
(DOX) is a compound that is applied during the treatment of many solid tumors
[65] because it is one of the most effective chemotherapeutic agents. Therefore,
extensive work has been done to find an analog of DOX, such as epirubicin, which
is less toxic and does not lead to drug resistance [66].
The second strategy for reversing therapy resistance is administering chemosen-
sitizers together with standard treatment. The most important mechanism of
MDR is overexpression of ABC transporters, which are responsible for low-drug
bioavailability by pumping the drug out of the cells. Verapamil was the first
chemosensitizer approved by the FDA to target ABC transporters [67].
The third method for addressing a treatment-resistant tumor is so-called targeted
therapy, which targets specific signaling pathways that are upregulated in resistant
10
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tumor using, for example, small molecule inhibitors (SMIs). SMIs are small
molecules (around 500 Da) that block the activity of key molecules and, thus,
suppress the proliferation and differentiation of tumor cells [68]. For instance,
NSC23925 SMI is an effective inhibitor of P-glycoprotein (also known as MDR1
protein) in ovarian cancer. Recent studies have shown that NSC23925 could prevent
resistance to paclitaxel in ovarian cancer [69].
The application of delivery systems is the fourth method to target resistance to
treatment in a cancer patient. One of the goals of these systems is to increase
drug concentration, especially in solid tumors, by relying on vascular permeability
and ineffective lymphatic drainage. One example of nanomedicine that has been
approved by the FDA [63] is Doxil (PEGylated liposomal Dox), which encapsulates
DOX and delivers it to the tumor using a vesicle called liposome.
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4 Mathematical models of treatment resistance in can-
cer
Many computational tools are available to model treatment resistance in cancer.
These can be divided into two groups: i) mechanistic modeling and ii) data-driven
predictive modeling [70]. The first group is comprised of dynamical models that
describe mechanisms of therapy resistance from a molecular or cellular point of
view whereas data-driven predictive modeling applies various omics data to create
a probabilistic model to identify for example biomarkers for treatment resistance.
This thesis focuses on the development of a mechanism-based mathematical model.
A kinetics model of the p53 signaling pathway was developed to study radio-
resistance in a solid tumor, and a stochastic model of platinum resistance in ovarian
cancer was created to investigate mechanisms of platinum resistance in HGSOC.
The main focus of this thesis is stochastic modeling of platinum resistance in
HGSOC; therefore, this chapter discusses stochastic models of tumor evolution
following description of two models of chemotherapy.
4.1 Models of treatment resistance evolution in cancer
The accumulation of various random (epi)genetic aberrations is one of the reasons
for resistance to cancer treatment. Therefore, stochastic mathematical models are
powerful mathematical tools to study treatment resistance. Stochastic models of
evolution can be for example in form of: i) the Moran model, ii) the Wright-Fisher
model, and iii) the branching model [71]. Figure 5 presents a schematic of these
three models.
4.1.1 Constant population size models
The Moran and Wright-Fisher models both assume a constant population size.
This means that the number of cells is constant during the entire course of the
simulation. Such models have been widely applied to study the effects of various
evolutionary forces, such as genetic drift and natural selection [72]. Both models
are discrete-time models, which means the state of the system is updated at finite,
constant time intervals.
The Moran process model assumes that generations overlap and the population size
12
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remains constant, N, with m different types of cells [73]:
N =
m
∑
i=1
Ni,
where Ni is the number of cells in subclone i. Each subclone can have a different
fitness value f1, f2 . . . fm. During each time step, one cell of type i is chosen to
divide with a probability that is proportional to its fitness value, fi. Subsequently, a
random cell is chosen to die, and to be replaced by another cell, chosen from with
probability influenced by its selective value, which leads to the following equation,
which describes the probability that cell type i increases and cell type j decreases
[71]:
P(Ni → Ni+1,Nj → Nj −1) = Ni · fi∑mk=1Nk · fk
Nj
N
.
The major drawback of the Moran process model is that the model is computation-
ally expensive to simulate. Modification of the Moran process model, called the
Wright-Fisher model, was proposed [74, 75]. In contrast to the Moran process, the
Wright-Fisher model samples the whole population with a probability distribution
in every generation; therefore, the model assumes that generations do not overlap.
Wright–Fisher model involves sampling with replacement from the population at
generation t to derive the population at generation at t+1. Assuming the simplest
scenario with two types of cells, Ni and Nj cells, and given a total population size
N, the probability of cell type i contain Nii cells at the next generation follows the
binomial distribution:
P(Ni → Nii)≈ Bin(Nii;N, Ni · fi∑mk=1Nk · fk
).
The Moran process and the Wright-Fisher model are related to each other. One
generation of the Wright-Fisher model equals n generations of the Moran process,
and both models lead to similar results. For example, fixation probabilities are
almost identical in both models. Although the Moran process model has the benefit
of more accurate analyses, the Wright-Fisher model is much more efficient from a
computational perspective.
4.1.2 Fluctuating population size model
The most widely applied model with a fluctuating population size is the branching
process model [76]. It is a Markov process model where each individual produces
offspring with rate λ during time-interval between t and t+Δt independently of
other individuals. In the simplest scenario, one of three processes is possible at a
13
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Figure 5: Mathematical models of drug resistance evolution. Three models of evolution
are presented in the Figure: Moran process, Wright—Fisher, and branching process
model (Adapted from [71].
given time-interval: i) division without mutation (symmetric division) with rate
λ (1−u), ii) cell death with rate d, and iii) division with a mutation leading to the
emergence of a new type of cell with mutation rate λ ·u (asymmetric division). The
rate of each event is independent of population composition and size.
In case of two type of individuals (A and B), the probability of each event after very
short time interval Δt is given with the following equations:
P(Na+1(t+Δt);Nb(t+Δt)|Na(t),Nb(t)) = λ (1−u)Na(t)Δt+λuNb(t)Δt
P(Na(t+Δt);Nb+1(t+Δt)|Na(t),Nb(t)) = λ (1−u)Nb(t)Δt+λuNa(t)Δt
P(Na−1(t+Δt);Nb(t+Δt)|Na(t),Nb(t)) = d ·Na(t)Δt
P(Na(t+Δt);Nb−1(t+Δt)|Na(t),Nb(t)) = d ·Nb(t)Δt
14
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where Na and Nb is number of individuals in a subclones A and B, respectively.
The branching process is a powerful tool for modeling the stochastic growth of
a tumor assuming exponential tumor growth. The model was applied to answer
various urgent questions in oncology such as i) What is the probability of metastasis
of pancreatic cancer [77], ii) What is the selection advantage of somatic mutations
in cancer [78], and iii) What is the probability of intrinsic resistance to ibrutinib in
chronic lymphocytic leukemia [9].
4.2 Modeling chemotherapy treatment
The mathematical models presented in the previous section consider unperturbed
tumor growth without treatment intervention. However, it is also important to model
tumor dynamics under treatment, especially when attempting to model acquired
drug resistance in cancer patients. This section reviews two of the most common
models for chemotherapy that could be combined with models of tumor growth.
Skipper–Schabel model
The oldest model of chemotherapy is the Skipper-Schabel model, which is known
as the log–kill hypothesis [79]. This hypothesis states that when the tumor grows
exponentially (increasing in size by a constant fraction every fixed-time interval),
the tumor also shrinks by a constant fraction called log-kill in the presence of
chemotherapy. This model can be defined with the following equation:
N˙(t) = λ ·N(t)−C ·N(t),
where λ is growth rate and C is drug concentration.
The Skipper-Schabel model is also known as the second Skipper law, which states
that the fraction of cells killed by a given drug dose is constant (independent of
tumor burden); therefore, a linear increase in dose size causes a log increase in the
cell kill rate [80]. For example, if drug dose C shrinks the tumor size from 1010
cells to 109 and kills 90% of cells (one-log kill), the same dose will reduce the
tumor burden from 109 to 108.
Norton–Simon model
The log-kill model assumes that tumors grow exponentially. While this assumption
is valid for liquid tumors, the growth dynamics of solid tumors follow Gompertzian
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growth dynamics. Norton and Simon developed the following model to describe
chemotherapy in solid tumors:
N˙(t) = f (N(t))(1−C(t)),
where f (N(t)) represents the growth dynamics of unperturbed tumor growth rate
and C(t) is drug concentration.
Norton–Simon formulated the following hypothesis of chemotherapy treatment
based on the above model: "Therapy results in a rate of regression in tumor volume
that is proportional to the rate of growth that would be expected for an unperturbed
tumor of that size."[81]
L. Norton and R. Simon developed a hypothesis that is now the basis for a novel
strategy in cancer treatment called dose-dense chemotherapy [81]. Based on this
theory, smaller tumors grow faster and are, thus, simpler to eradicate than a large
tumors. Therefore, L. Norton and R. Simon suggest that the best way to eliminate all
tumor cells is to administer chemotherapy with the same dose but more frequently
than standard chemotherapy in order to minimize the risk of tumor regrowth between
chemotherapy cycles. This hypothesis was successfully validated in the clinical
trial 20 years later [82].
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5 Mathematical model analysis
After constructing and calibrating the model, the next crucial step is analyzing its
behavior. Model analysis is an integral part of the modeling process. This section
reviews two of the most common methods for model analysis: sensitivity and
bifurcation analyses.
5.1 Sensitivity analysis
Estimating the precise parameter values for a mathematical model is one of the
challenges of mathematical modeling. The lack of precise values can be addressed
by performing a sensitivity analysis (SA) that allows for the quantification of
uncertainty in the model outputs.
There are three main applications of SA, and the most important is model devel-
opment. SA is applied extensively to guide parameter estimation and check the
correctness of the model’s assumptions [83]. The second application of SA is the
reduction of a mathematical model [84]. The major challenge of systems biology is
to reduce the mathematical model defined with hundreds of equations in order to
perform model simulations in an acceptable amount of time with limited memory
while preserving the qualitative model behavior. The third application of SA is
finding parameters that are sensitive to the output. For example, SA can facilitate
searching for new drug targets in cancer or optimize the drug dose and schedule by
checking the model parameters that most affect output, such as overall survival [85].
SA can be divided into two types: local SA (LSA) and global SA (GSA). The LSA
involves perturbing the nominal parameter value by a small amount and calculating
the effect it has on the output. The GSA method requires changing the parameter
values over a wide range to assess its impact on the model output.
5.1.1 Local methods
Some mathematical models can be described as a system of ordinary differential
equations:
dyi
dt
= fi(yi, p, t) i= 1,2, . . . ,n,
where yi is a vector of variables and p is a vector of model parameters. The effect
of a small parameter change can be expressed as a Taylor series expansion:
yi(t, p+Δp) = yi(t, p)+
m
∑
j=1
∂yi
∂ p j
Δp j +
1
2
m
∑
l=1
m
∑
j=1
∂ 2i
∂ pl p j
Δp j pl + . . .
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where the first–order local sensitivity coefficient equals ∂yi∂ p j and form sensitivity
matrix:
S(t) = {si j}= { ∂yi∂ p j }
The sensitivity coefficient describes the effect on the ith output as a result of a small
change in the jth parameter around its nominal value. The sensitivities coefficients
can be approximated using the finite difference method (indirect method) where
sensitivity coefficients are given in the following formula:
si j ≈ yi(p j +Δp j, t)− yi(p j, t)Δp j
In this method, the model is solved at the nominal parameters values and then at
some perturbed value of parameter p j while the other parameters are kept at theirs
original values.
5.1.2 Global methods
LSA is applied to study the model outcome in the neighborhood of nominal
parameter values, i.e., locally. However, the values of the model parameters can
vary widely in biological systems. Therefore, a global sensitivity analysis is applied
to quantify the model sensitivity for a wide range of input parameters [86].
The simplest global SA methods are based on sampling. The sampling–based
methods use Monte–Carlo (MC) techniques to investigate the relationship between
model inputs and outputs. For a model with m inputs p= {p1, p2 . . . pm} a sampling
method consists of three steps:
1. Generate N values of parameter pi from given probability distribution,
2. Evaluate the model for each element in the input sample and extract model
outputs,
3. Quantify and map inputs with outputs.
The most popular sampling method applied in GSA is Latin hypercube sampling
(LHS). GSA requires that the entire input space is sampled appropriately, which
requires a large number of samples. This becomes a problem when the model
requires intensive computational simulation. Thus, the LHS method was proposed
as a more efficient way to sample inputs from the probability distribution [87].
In one-dimensional LHS, the cumulative density function is divided into equal N
partitions, and then a random number is sampled from one partition. In this way,
LHS ensures that the entire range of input is covered.
The simplest method to map input with output is to create a scatter plot with an
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input on the x-axis and an output on the y-axis. When the effect of one input on
one output is measured, the method is called “one factor at a time” (OFAT). This
approach is impractical when there are many parameters in the model because it
requires the generation and evaluation of many plots. Therefore, regression and
correlation methods have been applied to estimate qualitatively global sensitivity.
Perhaps the most widely used tool is the partial rank correlation coefficient analysis
(PRCC) where a partial rank correlation is calculated for the model inputs and
outputs [88, 89].
5.2 Bifurcation analysis
In biological systems, values, among others, of protein synthesis rate or protein
degradation rate are not constant but vary depending on for example the environment.
Thus, to create a mathematical model of the biological system, it is important to
study qualitatively model behavior when the values of the parameters vary several
fold times.
Bifurcation analysis is a mathematical tool that is used to study the boundaries
between regions in a wide parameter space where the qualitative behavior of a
system varies drastically [90]. Therefore, a bifurcation analysis is performed to
analyze a qualitative change in system behavior as a result of variation in a parameter
(codim 1) or parameter values (codim >1).
Bifurcation theory has three practical applications. The most important one is in
investigation boundaries between several types of dynamics of a biological system,
such as a specific signaling pathway. It allows describing the behavior of the
signaling pathway which behaves differently depending on environmental factors
[83]. The second practical application is the adjustment of parameter values to
obtain the desired system dynamics [91]. It is known as inverse bifurcation analysis.
The last practical use of bifurcation analysis is to find the exact bifurcation point
which is difficult to find experimentally [92]. One example of this application could
be finding bifurcation points of cell cycles, which define the transitions between
different cell cycle phases [93].
The most commonly observed bifurcations in biology are saddle-node and Hopf.
The saddle-node bifurcation is also known as the fold bifurcation, and it is observed
when two fixed points (the first is the saddle and the second is the node) collide and
annihilate each other. In biology, this bifurcation is observed when the biological
system works like a bi-stable switch. The most popular switch is the so-called
toggle switch, which is frequently found in gene regulation [90]. Hopf bifurcation,
on the other hand, is observed when a steady state solution becomes a periodic
19
5 MATHEMATICAL MODEL ANALYSIS
solution as a result of change in the parameters values. Thus, Hopf bifurcation
occurs when oscillations appear in the biological system.
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6 Aims of the study
The main goal of this thesis is to develop mathematical models of resistance to
treatment in solid tumors and apply them to suggest novel strategies to revert therapy
resistance. The research aim can be divided into the following steps:
1. Develop a mathematical framework based on bifurcation theory and siRNA
control to investigate how to restore proper functioning of the p53 pathway
2. Develop a stochastic mathematical model of innate resistance to platinum-
based chemotherapy using longitudinal clinical data
3. Develop a mathematical framework to simulate a cohort of HGSOC patients
4. Develop a model of targeted therapy for HGSOC and simulate clinical trials
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7 Materials, Methods, and Models
This thesis uses clinical data from advanced HGSOC patients and integrates them
with mathematical modeling. An approximation of the stochastic simulation
algorithm and numerical methods for solving ordinary differential equations (ODEs)
were applied to achieve the model simulations. KM, SA, and bifurcation analyses
were used to analyze the models. Table 1 presents the main methods used in this
thesis.
Name Category Used in publication
Clinical data from HGSOC treated in TUH data II, III
TCGA clinical data from HGSOC patients data II, III
Branching process model method II, III
p53 signaling pathway model method I
Stochastic simulation algorithm method II, III
Kaplan–Meier analysis method II, III
Sensitivity analysis method II, III
Bifurcation analysis method I
Table 1: Summary of methods.
7.1 Clinical data
In this thesis, clinical data from patients with advanced HGSOC were collected to
calibrate and validate the model. Firstly, the data from Turku University Hospital
(TUH) were applied to calibrate the mathematical model (calibration cohort), and
the data from TCGA were used as a validation cohort. Table 2 summarizes the
patient characteristics.
The clinical data used in this thesis include the treatment schedule, response to
primary treatment, progression data, and information about the tumor at the time of
diagnosis, such as tumor stage and patient age. The key clinical parameter extracted
from the clinical data is the platinum-free interval (PFI), which is measured as the
time interval from the last date of platinum-based chemotherapy to relapse. PFIs
were applied in the simulation framework to reproduce a real patient’s response to
therapy.
The calibration cohort includes data collected from HGSOC patients treated at TUH
between 2009 and 2016. All of the patients were diagnosed as inoperable at the
time of diagnosis and were, thus, treated using the NACT approach. That is, the
patients were referred to the median of three cycles of NACT. The patients that
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responded to NACT underwent interval debulking surgery, and patients that did not
respond to NACT were referred to alternative or palliative treatment.
In addition, for the 26 HGSOC patients in the calibration cohort, 18F–fluorodeoxy-
glucose positron emission tomography/computed tomography (18F–FDG PET/CT)
was performed before diagnostic laparoscopy and after median of the three NACT
cycles [96]. Next, the metabolic tumor volume (MTV) was extracted from the
18F–FDG PET/CT scans as a measure of tumor burden and converted from tumor
volume to the number of cancer cells [97]. The data were applied to calculate the
initial response to platinum-based chemotherapy in advanced HGSOC patients.
The validation cohort included data from the Cancer Genome Atlas (TCGA) where
clinical data for 489 serous ovarian carcinoma patients are available. The patients
were selected based on the following criteria: i) grade >1, ii) stage IIIb-IV, iii)
patient underwent surgery, and iv) patient was treated with a platinum-taxane
combination or platinum alone. After applying these selection criteria, a validation
cohort of 170 HGSOC patients was created.
Characteristic Calibration (n = 62) TCGA (n = 170)
Age at diagnosis (years) 66 59
Tumor stage (FIGO 2009)
IIIB 1 9
IIIC 37 134
IV 24 27
Residual tumor after DS
0 14 26
1 to 10mm 27 87
>10mm 4 57
NA 16 0
Primary chemotherapy regimens
Platinum 9 7
Platinum – Taxane 53 163
Primary therapy outcome
Complete response 28 115
Partial response 13 25
Stable disease 0 8
Progressive disease 20 9
NA 1 13
Platinum-free interval (months) 5 7
Progression-free survival (months) 10 13
Overall survival (months) 18 37
Table 2: Summary of clinical data applied in the thesis. The data are presented as
median or a number of patients. (adapted from Publication II)
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7.2 Branching process model
The simplest branching process model is the Galton-Watson (G-W) model, which
is also known as a discrete-time, discrete-state branching process model [76]. The
model assumes a homogeneous population of X individuals, such as living cells.
At every time step, each individual produces offspring independently of each other
with rate λ . The dynamics of the number of cells in each generation is given using
the following recursion formula:
Xn+1 =
Xn
∑
j=1
ξ (n)j .
where {ξ (n)j : j= 1,2, . . .} is a set of independent and identically distributed random
variables being equal to the number of progeny of the i-th individual (cell) of the n-th
generation. The idea behind the G-W model is that individuals reproduce asexually,
independently, and with the same distribution of offspring. The simplicity of the G-
W process makes it frequently applied tool when studying processes of proliferation
in biology and is applicable whenever the hypothesis of non-overlapping generations
is justified.
The model can be modified easily to continuous-time discrete-state model as
follows. A single individual (ancestor) is born at t = 0 and lives for time τ
which is exponentially distributed with parameter λ . At the moment of death,
the individual produces offspring according to the probability distribution with
probability generating function f (s). Next, each of the individuals in the next
generation, behaves independently of each other, in the same way as the initial
individual. It lives for a time interval equal to τ and produces a random number
of offspring. Figure 6 presents four examples of simulations using the modified
G-W model which is essentially identical to age-depended branching process model
presented in chapter four in monograph [76].
Population growth can be modeled in continuous time also with a birth-death model.
In that model, individuals produce offspring with the rate b throughout their lifetime,
instead of reproduction only at the moment of death.Individuals die with the rate d,
so that their life time is again exponentially distributed. The birth rate b can also be
interpreted as the cell division rate when modeling the growth of cell populations.
In that case the birth-death model can be interpreted as a continuous-time branching
process model, in which life time is exponentially distributed with parameter b+d,
and at the moment of death, an individual produces two offspring with probability
b
b+d and zero offspring with probability
d
b+d . The transition probabilities for a
simple birth-death process define the probability of a birth or death in a short period,
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Δt, as follows: pi j(Δt) =
⎧⎪⎪⎪⎪⎪⎨
⎪⎪⎪⎪⎪⎩
biΔt, when j = i+1
diΔt, if j = i−1
1− (b+d)iΔt if j = i
0, otherwise
The time increment Δt is chosen so that it is short with respect to the expected cell
life-time which equals 1/λ .
The model can also be expanded to a multiple-type individual case where we assume
that at time of division, an individual has probability b ·u to divide to a new type,
where u is transition rate. The thesis focuses on the multiple–type continuous-time
branching process where each cell type (subclone) has accumulated a different
number of treatment resistance mechanisms.
Figure 6: Exemplar four simulations of pure birth branching process model (left) and
birth–death branching process (right). Each line shows one simulation starting from a
single cell.
7.3 P53 signaling pathway model
P53 is the most crucial protein dysregulated in cancer. It is known as "the guardian
of the genome" [94] because it is activated when DNA damage is detected, and
its role is to stop the cell cycle and start the DNA repair program, and if it fails,
to initiate apoptosis. Protein p53 is deactivated in half of the tumor types, and
the p53 signaling pathway is the most frequently dysregulated pathway in cancer
besides the MAPK pathway [95, 96]. Moreover, a mutation in p53 is connected to
resistance to chemotherapeutic agents, such as cisplatin and doxorubicin [97, 98].
Figure 7 presents a schematic of a model applied in this thesis, Equations 1–4
describe the model, which is given in the form of the system of ordinary dif-
ferential equations, and Table 3 lists the model parameters. This toy model of
p53|Mdm2|PTEN system is based on two publications [99, 100]. The first shows
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the appearance of oscillations in the system as a result of DNA damage, and the
second publication describes the bi-stability of the p53 signaling pathway thanks to
the positive feedback loop.
d p53
dt
=p1−d1 p53(Mdm2n)2 (1)
dMdm2cyt
dt
=p2
(p53)4
(p53)4+(k2)4
− k1 (k3)
2
(k3)2+(PTEN)2
Mdm2cyt −d2Mdm2cyt
(2)
dMdm2n
dt
=k1
(k3)2
(k3)2+(PTEN)2
Mdm2cyt −d2Mdm2n (3)
dPTEN
dt
=p3
(p53)4
(p53)4+(k2)4
PTENswitch−d3PTEN (4)
In the model, p53 is produced spontaneously, and its level is regulated by the rate
of his degradation controlled by Mdm2. The level of p53 is governed by positive
and negative feedback loops. P53 actives cytoplasmic Mdm2 (Mdm2cyt) and then
Mdm2 is transported to the nucleus (Mdm2n). Finally, Mdm2 degrades p53. It is a
negative feedback loop inhibiting the possibility of a high level of p53. P53 also
activates PTEN which inhibits transport of Mdm2 to the nucleus. It is a positive
feedback loop which by inhibition of transport of Mdm2 to the nucleus, allows the
increase of the level of p53.
Next, a more detailed model of the p53 signaling pathway was modified by the
removal of system control by Nutlin, and the inclusion of irradiation (IR) and siRNA
control. A schematic of the model is presented in Figure 1 of Publication I. The
equations for the model are listed in the Supplementary Materials of Publication I.
7.4 Stochastic simulation algorithm
There are two main methods to solve mathematical models of biological systems:
deterministic and stochastic ones depending on how the model is formulated. The
deterministic methods include numerical algorithms to solve, e.g., the system of
ODE whereas stochastic ones include methods to simulate biological systems by
taking into account its heterogeneity.
Here, a method called the stochastic simulation algorithm (SSA) will be described
as it is the most frequently applied method to simulate biological systems by taking
into account stochasticity [101]. The most popular SSA method is called the
Gillespie algorithm where the rate of each reaction is Poisson-distributed.
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Figure 7: Schematic of the toy model of the p53 signaling pathway described in
Equations 1–4. A solid line shows a transition from one type of molecule to another, and
a dotted line represents activation. The arrow that ends with a vertical line represents
inhibition.
In this thesis, the SSA was applied to simulate the dynamics of heterogeneous
tumor mass, where many subclones are observed. As the appearance of a new
subclone in the model simulation is a stochastic process, and the probability of
a new mutation (and the emergence of a new subclone) is several folds smaller
than the probability of faithful division, the SSA is the best method to simulate
the evolution of drug resistance. Moreover, this algorithm allows us to simulate a
heterogeneous population of patients.
Figure 8 presents a schematic of so-called direct method SSA, which works by
answering two questions at each step of a simulation:
1. When will the next event occur?
2. Which event will happen next?
The Gillespie algorithm is easy to implement on a computer. First, we need to
provide the population size for each species as the initial data. Next, we need
to set all the possible interactions in the system by giving the event rate constant
and a so-called transition matrix. Then, the propensity of each event is calculated
according to the formula:
aμ = hμ ·Cμ ,
where hμ is the number of all possible substrate combinations, and cμ is the event
rate constant. The next step is to generate two random numbers from uniform
probability distribution between 0 and 1 that calculate the time of the next event and
to determine which event will happen according to the formulas shown in Figure 9.
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Symbol Value Description
p1 8.8
[ 1
s
]
spontaneous production of p53
p2 440
[ 1
s
]
Mdm2cyt production rate
p3 100
[ 1
s
]
PTEN production rate
d1 1.375 ·10−14
[ 1
s
]
p53 degradation
d2 1.375 ·10−5
[ 1
s
]
Mdm2cyt degradation rate
d3 3 ·10−5
[ 1
s
]
PTEN degradation rate
k1 1.925 ·10−4
[ 1
s
] transport rate of Mdm2cyt to nucleus
k2 105 inhibition constant for transport of
Mdm2cyt to nucleus
k3 1.5 ·105 activation constant for PTEN
DNAdamage 0−9 [a.u.] level of DNA damage
PTENswitch 1 strength of positive feedback loop
SiRNAdose 0−1 [a.u.] level of siRNA
Table 3: List of mathematical model parameters of mechanistic p53 signaling pathway
model presented in Figure 7 .
Finally, the system is updated. The process continues until no reaction can happen
or until the given simulation time.
7.5 Kaplan-Meier survival analysis
The Kaplan–Meier estimator is a statistical method that measures the survival
probability over time by taking into account incomplete data [102]. In medicine,
K-M analysis can be applied for example to estimate the fraction of patients who
survive at a given time after treatment. It is the most widely used method for
comparing two different arms in clinical trials. This thesis uses the K-M analysis
to calibrate the stochastic model of innate drug resistance by taking into account
real-life responses.
The Kaplan-Meier survival plot is defined as the probability function of surviving
during a given period. Three assumptions are used in this analysis: The first is that
patients who are censored have the same survival prospects as those who continue
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Figure 8: Schematic of stochastic simulation algorithm.
to be followed. In the second assumption, the survival probabilities are equal for
patients who are recruited to the study at earlier or later phases. Third, it is assumed
that the event happens at the exact time specified. In reality, an event, such as tumor
recurrence, would not occur precisely at the time of the medical examination but
between two follow-up appointments [103].
Formally, the Kaplan–Meier analysis is performed by calculating the survival
probability at a given time using the following formula:
St =
number of subjects living at start−number of subjects died
number of subjects living at start
.
St is calculated as the number of surviving patients, divided by the number of
patients at risk at a given time. Patients who are marked as "censored" because,
for example, they dropped out, are not counted as "at risk." Therefore, censored
patients are not counted in the denominator in the St equation. The total survival
probability is calculated by multiplying all the probabilities at all time intervals that
precede that time.
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8 Results
This thesis uses the integrative mathematical oncology approach to investigate
resistance to radiotherapy. Using a model of p53 signaling and siRNA control, we
suggest a method to revert radio-resistance in cancer cells with damaged signaling
pathways, which are responsible for apoptosis. Next, we develop a model of
platinum resistance in advanced HGSOC and integrate it with longitudinal clinical
data. The model is also used to find a novel drug combination for patients with
advanced HGSOC using clinical trial simulations. Table 4 presents a summary of
the results.
Name Category Used in publication
Application of bifurcation analysis and
siRNA to radioresensitization
method I
Stochastic model of innate platinum resis-
tance in HGSOC
model II, III
Virtual HGSOC patient cohort simulation
approach
method II, III
Integration of clinical data into mathematical
model
method II
Virtual clinical trials simulations in HGSOC tool III
Mathematical modeling targeted therapy in
HGSOC
method III
Table 4: Summary of results.
8.1 Radiosensitization using siRNA and bifurcation theory
Many types of p53 signaling dysregulations have been observed in cancer cells,
whose repair could be vital in designing cancer treatment [104, 105]. This section
investigates two types of p53 pathway damage: i) overexpression of p53 inhibitor,
Mdm2, which is observed in 40% of cancer types such as osteosarcoma [106], and
ii) silencing the PTEN protein that is observed for example in breast cancer [107].
PTEN is an inhibitor of the AKT pathway that is responsible for cell proliferation.
The absence of this protein leads to uncontrolled cell growth. In the proposed
model with system of ODE 1–4, the first p53 dysregulation is implemented by
increasing production rate of Mdm2 (p2 new = 8 · p2) whereas the second one by
setting PTENswitch to zero.
The main goal of performing a bifurcation analysis on a toy model of the p53
pathway is to investigate how disruption in the signaling pathway can change its
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dynamics. This type of analysis has two applications in cancer research: i) to find
a biomarker for a given type of cancer, and ii) to discover novel drug targets that
restore proper functioning to the p53 signaling pathway. This thesis focuses on the
second application and suggests siRNA as a means to control the dynamics of the
p53 pathway.
Figure 9: Bifurcation diagrams for healthy cells, MCF–7 cells (breast cancer), and
SJSA–1 cells (osteosarcoma). Two bifurcation plots are shown for cells with damaged
positive and negative feedback loops (MCF–7 and SJSA–1): the first considers a case
without siRNA (left plot) and the second considers a case with siRNA (right plot). The
solid and dotted lines represent stable and unstable equilibrium points, respectively.
Figure 9 presents the bifurcation plots for healthy, MCF–7, and SJSA–1 cells. The
level of DNA damage was chosen as the bifurcation parameter. In healthy cells, the
p53 signaling pathway behaves like a bistable switch. That is, low DNA damage
activates the DNA repair pathway through a transient increase in the p53 level,
which goes back down after the DNA is repaired. Intermediate DNA damage
leads to bistability. That is, the cell can activate the DNA damage process, and
the level of p53 goes back down or activates apoptosis by increasing the p53 level.
Finally, a high level of DNA damage leads to a high level of p53 and activation
of programmed cell death. In MCF-7 cells, we observe a drastic change in the
dynamics of the p53 pathway. In this case, a system is monostable for a wide range
of DNA damage with a low level of p53. Therefore, the disruption of the positive
feedback loop makes it impossible for the cells to activate apoptosis. In SJSA-1
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cells, we observe a shift in the bifurcation diagram to the right. As a result, p53 is
activated in cells with a damaged negative feedback loop on a much higher level,
which requires a higher dose of radiation.
Next, a bifurcation analysis was performed in a case where siRNA was included in
the system to control the p53 pathway dynamics. As shown in Figure 9, the optimal
level of extortion by siRNA for a high level of DNA damage leads to restoration of
proper p53 dynamics in both types of cancer cells (MCF-7 and SJSA-1). Therefore,
in DNAdamage = 9 the phase portraits for both types of cells are identical to those of
healthy cells. Also, for SJSA-1 cells, the optimal level of siRNA leads to complete
restoration of proper dynamics and results in the same bifurcation plot as healthy
cells.
Finally, the results were confirmed using a detailed model of the p53 pathway,
which includes two types of extorsions: Mdm2 siRNA and PTEN siRNA. The
bifurcation analysis and p53 dynamics are in agreement with the results of the toy
model. Furthermore, the mathematical modeling framework, which was based on
the bifurcation theory, was extended to study the silencing of PTEN, using siRNA
to immunize healthy cells against radiotherapy.
8.2 Mathematical model of innate resistance to platinum-taxane
chemotherapy
Resistance to platinum-based drugs in ovarian cancer is a complex, multifactorial,
and dynamical process [108, 109]. It is complex because many signaling path-
ways, including the apoptosis pathway [110], are involved in platinum resistance.
Platinum resistance is also multifactorial because several platinum resistance
mechanisms are believed to accumulate in the tumor. Moreover, resistance to
platinum-based drugs is a dynamical process because most patients respond initially
to platinum-based chemotherapy but relapse after a median of six months. We have
developed a model of innate platinum resistance by taking these three properties of
platinum resistance into account.
Figure 10 presents a schematic of a platinum resistance mathematical model and
Table 2 in Publication II lists the model parameters used in this thesis. Briefly,
a multitype continues time branching process model where each type of cell can
undergo one of three processes: i) division to the same type of cell (faithful division)
with rate b(1−u), ii) division of the cell with an additional platinum drug resistance
mechanism (unfaithful division) with rate b ·u, and iii) death with a rate of d. The
model assumes an infinite number of possible subclones. That is, a wild-type cell
acquires one platinum drug resistance mechanism, which leads to a subclone called
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Figure 10: Schematic of the innate platinum resistance mathematical model, which
assumes an infinite number of platinum resistance mechanisms.
“1” that can acquire an additional platinum drug resistance, leading to a subclone
with two resistant platinum resistance mechanisms and so on. Therefore, the model
assumes an infinite number of possible platinum resistance mechanisms.
In addition to modeling the growth of sensitive and resistant cells, two types of
treatment interventions were modeled: platinum-based chemotherapy and debulking
surgery. Chemotherapy is included in the model using the cell log-kill hypothesis,
which increases the death rate in proportion to the birth rate. Debulking surgery is
modeled by removing a fraction of β cells. All types of cells are removed with the
same probability.
The major assumptions of the mathematical model are the following:
• Cells grow exponentially with a rate b.
• Cells with the acquired platinum resistance mechanism grow at the same rate
as wild-type cells.
• All platinum drug resistance mechanisms accumulate sequentially with the
same rate, u.
• During platinum-based chemotherapy, the rate of accumulation of platinum
drug resistance is the same as in the absence of chemotherapy,
• Drug toxicity is not explicitly included in the model.
The mathematical modeling effort aimed to answer two clinically relevant questions:
1. What is the number of platinum drug resistance mechanisms in the tumor at
the time of diagnosis?
2. How many platinum drug resistance mechanisms need to be targeted to
achieve significant improvement in the patient’s outcome?
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The first question was answered using simulations of HGSOC patients until the
diagnosis according to the standard of care in HGSOC. Next, a cell with the
maximum number of platinum drug resistance mechanisms was extracted from
the simulations. Finally, the average number of active platinum drug resistance
mechanisms was calculated for a virtual cohort of 1,000 patients. Based on the
model simulations, the advanced HGSOC patient accumulated five platinum drug
resistance mechanisms (minimum two and maximum seven platinum resistance
mechanisms) at the time of diagnosis.
The second clinical question was answered by simulating combination therapy.
It was assumed that for each platinum drug resistance mechanism, there was a
drug available with the same killing effect as the platinum-based chemotherapy.
Therefore, a cohort of 1,000 virtual patients was created, and one to six drugs
targeting platinum resistance were administered together with platinum. As we can
see in Figure 4 in Publication II, using more than three drugs to target platinum drug
resistance does not improve the platinum-free interval. Therefore, we concluded
that it was sufficient to target the three major mechanisms, even though five platinum
drug resistance mechanisms were present in the HGSOC patients at the time of
diagnosis.
8.3 Standard of care in advanced HGSOC simulator
This thesis develops a computer simulator of SOC in advanced HGSOC, which is
presented schematically in Figure 11. The simulator includes three phases: pre-
treatment, treatment, and post-treatment. The goal is to create a simulator that
captures real-life responses to HGSOC in silico.
For each virtual HGSOC patient, two parameters are sampled from lognormal
distribution before the simulation begins: i) tumor burden at diagnosis (M) and
ii) chemotherapy-induced death rate (dchemotherapy). Next, the pre-treatment phase
starts from a single wild-type cell, and the tumor grows according to the exponential
growth model in the absence of treatment interventions. The pre-treatment phase
ends when the total number of tumor cells is equal to M.
The treatment phase includes two types of interventions: i) platinum-based chemother-
apy and ii) debulking surgery according to NCCN [33]. Since clinical data
from patients in the calibration cohort are from patients who cannot be operated
at the time of diagnosis, the treatment phase is simulated as follows. First, a
virtual HGSOC patient is treated with three cycles of neoadjuvant platinum-based
chemotherapy. Next, debulking surgery is performed by removing at a one-time
point fraction of β cancer cells. Finally, three cycles of adjuvant chemotherapy are
administered.
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The last phase of simulation is called post-treatment. In this phase, the virtual
HGSOC patient has a small invisible tumor and no symptoms. This phase is
simulated as the pre-treatment phase where the tumor grows without interventions.
The phase ends when the tumor reaches Mrelapse = 109 cells, which is the smallest
detectable tumor size.
Figure 11: Schematic of standard–of–care simulations. The model simulation starts
from a single wild-type cell until the diagnosis – pre-treatment phase. Next phase is a
treatment consisting of platinum-taxane chemotherapy and debulking surgery. Finally,
the post-treatment phase is simulated until the first relapse, and PFI is calculated.
8.4 Integration of clinical data into mathematical model
The data from the calibration cohort were applied to estimate the model parameters.
In brief, MTV data from PET/CT scans at the time of diagnosis and after three cycles
of NACT were used together with the response data measured as the platinum-free
interval (PFI). Since this thesis focuses on primary treatment and the first relapse,
only the first PFI (the time interval between the end of primary treatment and the
first relapse) was measured. Figure 12 shows how the clinical data were integrated
into the model.
The PET/CT data at the time of diagnosis were applied to compute the probability
distribution of clinical diagnosis as a function of tumor burden (to estimate param-
eter M). The data were fitted to the following probability distribution function:
normal, exponential, Weibull, log-normal, logistic, and log-logistic. Next, the
Bayesian Information Criterion (BIC) was calculated for each distribution to
measure the goodness of fit (GOF) of the data to the probability distribution. The
best fit was obtained for log-normal distribution and was applied accordingly.
Furthermore, PET/CT data were applied at two-time points (at the time of diagnosis
and after NACT) to calculate the killing effect of platinum-based chemotherapy.
For each patient, this parameter was fitted using the bisection method to find the
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minimum value for the following objective function:
J = ˆMNACT −MNACT =
n
∑
i=1
(tNACT )−MNACT ,
where MNACT and ˆMNACT are the tumor burden after NACT and prediction based
on the model simulations, respectively. Based on these results, the killing effect
of platinum chemotherapy for each patient in the calibration cohort was estimated.
Next, the killing effect values were fitted to the probability distributions where the
best GOF was obtained for log-normal one.
Next, the PFI values were applied to find a value for the transition rate u. Firstly,
the K-M plot was created for the PFI data from the calibration cohort. As explained
in the previous section, SOC simulations were performed to generate a cohort of
1,000 virtual HGSOC patients. From these simulations, the PFI was extracted, and
the K-M plot was created in the same way as the PFIs from the calibration cohort.
Finally, the two plots were compared using the root mean squared error (RMSE).
The model was simulated for a wide range of u and compared to data using RMSE.
The value of parameter u with the smallest RMSE was chosen.
Figure 12: Integration of longitudinal clinical data into the mathematical model of
platinum drug resistance. The clinical data were applied to find the value of the
following parameters in the model: tumor burden at diagnosis (Mdiagnosis), transition
rate (u), and effect of platinum-taxane chemotherapy (dchemotherapy).
8.5 Mathematical modeling of targeted therapy in HGSOC
The next goal of the modeling effort was to suggest a combination treatment
to overcome platinum drug resistance. The results from genomic studies and
other mathematical modeling efforts show that ovarian cancer is already resistant
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to platinum at the time of diagnosis [111, 112]. Therefore, a combination of
platinum-based chemotherapy and a drug that targets the given platinum drug
resistance mechanism is suggested. Figure 13 presents the schematic model of
targeted therapy. In brief, three drugs were included: trientine, Wee1 inhibitor,
and birinapant, which are effective in treating pre-, on–, and post–target platinum
drug resistance, respectively. The drugs that were chosen via the literature review
have shown promise when combined with platinum-based chemotherapy and are
currently in the late stages of clinical trials.
The first drug included in the model is trientine, which targets platinum drug
resistance caused by reduced platinum drug uptake (pre-target resistance). It is
known that the active transport of a platinum drug into a cell is mediated through
copper transporter receptor 1 (CTR1). Trientine enhances Ctr-mediated platinum
transport to the cell. The drug is included in the model by increasing the killing
effect of the platinum drug in partially-resistant cells.
The second drug included in the model is Wee1 inhibitor, which targets on-target
platinum drug resistance. The Wee1 inhibitor inhibits Wee1 kinase, which is
responsible for the modulation of DNA damage response (DDR). The predominant
mechanism of action in Wee1 inhibitors is the failure of the G2–M checkpoint,
which occurs due to inappropriate CDK1/CCNB1 activation. Wee1 inhibition
also generates replication-dependent DNA damage in cells. Therefore, the Wee1
inhibitor re-sensitizes a cell to platinum-based chemotherapy. In the model, the
drug is included through a backward transition of a cell from fully-resistant to
partially-resistant and from partially-resistant to sensitive.
The third drug included in the model is birinapant, which is known as an inhibitor
of apoptosis (IAP). IAP is a crucial regulator of programmed cell death and hence
targeting post-target platinum drug resistance. The drug is included by adding
additional death to the model called apoptosis. In this process, a cell with a post-
target platinum drug resistance mechanism remains active but dies in the presence
of birinapant, creating an additional apoptotic death rate.
8.6 Virtual clinical trials simulations in HGSOC
In this thesis, virtual clinical trials simulations (VCTS) approach was applied to
answer two questions i) what is the effectiveness of platinum-based chemotherapy
combined with targeted therapy to overcome platinum drug resistance? And ii)
what is the benefit of targeting dominant platinum drug resistance mechanisms
using molecular biomarkers? Thus, two types of VCTS are performed: random-
ized controlled trial simulations RCTS and molecularly-stratified controlled trials
simulations MSCTS.
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Figure 13: Mathematical modeling of targeted therapy in HGSOC. we have included
three drugs trientine, Wee1 inhibitor, and birinapant, which target pre-, on- and post-
target platinum resistance, respectively.
Firstly, simulations have been performed for a combination of trientine, Wee1
inhibitor or birinapant with platinum-based chemotherapy. The best one–drug
combination was obtained for Wee1 inhibitor which triple PFI in comparison to
platinum-based chemotherapy alone. The worst combination is with birinapant
which gives only three months improvement in PFI. We can conclude that a drug
which re-sensitize cells to platinum-based chemotherapy leads to a better outcome
than a drug such as trientine which is directly killing resistant cells.
Next, two–drugs combinations were tested with platinum-based chemotherapy and
obtained that Wee1 inhibitor combined with birinapant gives the best outcome as the
PFI is equal to 30 months. The worst combination was for birinapant, and trientine
with PFI equals to 17 months. Finally, a combination of three drugs (trientine, Wee1
inhibitor, and birinapant) showed a massive reduction of tumor burden and PFI
equal to 34 months.
We have also performed clinical trials where biomarkers are applied to stratify
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patients into different treatment groups. Patients were stratified according to their
dominant platinum resistance mechanism. As Table 2 in Publication III shows,
the benefit of choosing patients positive to trientine and birinapant has four and
six months improvement in comparison to negative one, respectively. For Wee1,
however, no significant rise is observed. Based on MSCTS, the benefit of patient
stratification depends on drug efficacy and tumor composition.
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9 Discussion
The development of novel mathematical tools, together with advancements in
biological experimentation tools, has allowed for the emergence of a new field
called integrative mathematical oncology. This new field of cancer research focuses
on understanding cancer from a mathematical perspective. I used the IMO approach,
in this thesis, to study resistance to therapy in a solid tumor.
Specifically, this thesis focuses on understanding the resistance to radio- and chemo-
therapy in solid tumors on the molecular and cellular levels using mathematical
tools. Since evading cell death is one of the hallmarks of cancer and a cause of
therapy resistance, we focus on the p53 signaling pathway that regulates apoptosis.
Indeed, targeting this pathway could revert resistance to therapy in patients with
ovarian cancer, as well as other types of cancer [113, 114]. Next, we concentrated on
understanding resistance to SOC in patients with advanced HGSOC and suggested
novel combinatorial treatments for this aggressive type of cancer. In this case,
resistance to treatment was modeled on the cellular level.
In Publication I, we developed a mathematical framework that was based on
bifurcation theory and siRNA control to suggest a method to re-sensitize cancer
cells with two types of disruptions in the p53 signaling pathway to radiotherapy.
Since the p53 signaling pathway is one of the most commonly disrupted in solid
tumors, we created a kinetic model of this pathway for solid tumors. Next, an
inverse bifurcation analysis was performed to find the values of the parameters in
the dysregulated p53 signaling pathway which could restore its proper dynamics.
An analysis conducted on a toy model suggested silencing Mdm2, which is an
inhibitor of p53. Next, the model was validated using a more complex model of the
p53 signaling pathway.
The p53 signaling pathway is a very complex pathway with many negative and
positive feedback loops. Therefore, the creation of a more complex p53 signaling
pathway model that incorporates other important feedback loops would advance this
research. For example, it is known that the p53 signaling pathway has cross-talks
with the NFkB and ATM pathways. Testing this method on another commonly
dysregulated pathway, such as the MAPK pathway, which controls cell proliferation,
would be another way to advance this research.
In Publication II, we created a mathematical model of platinum resistance in
advanced high-grade serous ovarian cancer. In a previous modeling effort, platinum
resistance was assumed to be unifactorial; however, platinum resistance is in fact
multifactorial. Therefore, a stochastic model was built based on the branching
process, taking into account the multifactorial nature of platinum resistance. The
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model was applied to answer two vital clinical questions: How many platinum
resistance mechanisms are present at the time of diagnosis? And How many drug
resistance mechanisms need to be targeted to improve patient outcomes?
We applied longitudinal clinical data from advanced HGSOC patients to reproduce
an initial and long-term response to platinum. The initial response was measured us-
ing PET/CT scans, which showed that the median three cycles of NACT reduced the
tumor by 80%. The long-term response, however, was measured using a platinum-
free-interval with a median value of six months. Inter-patient heterogeneity was
also reproduced by sampling two clinical parameters from a random probability
distribution.
The platinum resistance model could be extended by modeling other treatment
strategies in ovarian cancer. For instance, another approach in SOC for HGSOC
patients is primary debulking surgery followed by adjuvant chemotherapy. Besides,
the model presented in this thesis does not consider a combination of platinum
chemotherapy and maintenance therapy with bevacizumab, which is being applied
more frequently in clinics. Thus modeling bevacizumab treatment could advance
this research.
In Publication III, we created a model of platinum resistance, which considered three
platinum resistance mechanisms: pre-, on-, and post-target. Next, we combined it
with a model of targeted therapy that includes three drugs: trientine, Wee1 inhibitor,
and birinapant, which are effective at treating pre-, on-, and post-target resistance
mechanisms, respectively. We also suggested a novel mathematical method to
calculate the drug efficacy of a drug that is currently in the late stage of a clinical
trial.
In Publication III, we applied a virtual clinical trial approach to estimate the benefits
of targeted therapy in advanced HGSOC. We performed two types of VCTS: i)
a randomized controlled trial (RCT) and ii) a molecularly stratified controlled
trial (MSCT). The first trial estimated the effectiveness of targeted therapy in the
non-stratified HGSOC patient cohort. Based on the VCTS, Wee1 inhibitor was
identified as the most effective drug, which means that a drug that re-sensitizes cells
to platinum provides the best outcome in terms of longer PFI. Next, we performed
an MSCTS to investigate the benefits of targeting the dominant drug resistance
mechanism. The simulations showed the benefits of patient stratification based on
a dominant platinum resistance mechanism when using two out of three drugs. It
indicates that targeting the dominant platinum resistance mechanism could prolong
PFI.
The model of platinum resistance combined with a targeted therapy could be
advanced, among others, by incorporating drug toxicity. The model presented in
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this thesis assumes that drugs kill cancer cells but do not affect healthy cells. Even
though a combination of platinum with one targeted drug shows acceptable toxicity,
it might not be tolerated in a combination of two or three drugs. The model could
also be extended by modeling the pharmacokinetics of the drug, which would allow
for optimization of the drug dose.
In conclusion, the mathematical oncology approach was applied to understand the
resistance to chemotherapy and radiotherapy in solid cancers on the molecular and
cellular levels. We suggested a method to overcome radio-resistance in breast cancer
and osteosarcoma by applying bifurcation theory and siRNA control. Next, we
built a model of platinum resistance in HGSOC on the cellular level and modeled
the evolution of various subclones with different levels of platinum resistance.
Integrating the model with longitudinal clinical data allowed us to answer urgent
clinical questions related to ovarian cancer. Finally, the VCTS approach was used to
suggest novel drug combinations in HGSOC that could improve patient outcomes.
As a future development, IMO will continue to integrate longitudinal clinical
and multi-omics molecular data with mathematical modeling to create a patient-
specific model. Current mathematical models have not been applied successfully
in the clinical setting since model parameters are estimated based on data from
in vitro and in vitro experiments. Models that are based on clinical data have the
advantage of being based on information that is directly extracted from patients.
Next, the development of mathematical tools allowing integration of patient’s
data with mathematical modeling will continue. Lastly, advances in hybrid and
multiscale mathematical modeling will allow modeling tumor on several scales
simultaneously.
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